COMPANY

PharmaIN Corporation

HQ: Bothell, WA source · pharmain.com ↗ · West Coast

Keywords: subcutaneous portal hypertension inflammatory diseases cirrhosis type 1 diabetes osteosarcoma psoriasis Liver Cirrhosis Liver Fibrosis Ascites Hepatic sexual arousal disorder PHIN-214

Location: Bothell, WA · source · Oct 15, 2026

Profile checked Oct 10, 2026

1Trials (company is sponsor)39NIH grants

Timeline

Aug 20, 2025 Grant Government grant — SBIR: $2.64M (annual award, as published), announced Aug 20, 2025. Agency: NIH/NIDDK. Source: government award database. source ↗
Jan 3, 2022 Trial start Phase 1: Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics source ↗

Funding

Last 2 years.

Aug 20, 2025 Government grant — SBIR: $2.64M (annual award, as published), announced Aug 20, 2025. Agency: NIH/NIDDK. Source: government award database. source ↗

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT05490888	Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics	Phase 1	Recruiting	Jan 3, 2022	May 31, 2026 (estimated)

NIH awards 39

Annual award amounts. Total $21.2M.

Sep 17, 2024 NIH award 2R44DK103553-05 FY2024: $2,145,275 awarded for that fiscal year; activity R44 (SBIR); PI CASTILLO, GERARDO M.; recipient as written: PHARMAIN CORPORATION, BOTHELL, WA. Subcutaneous Drug Development for Port source ↗
Aug 16, 2024 NIH award 5R44CA278570-02 FY2024: $995,099 awarded for that fiscal year; activity R44 (SBIR); PI ALFARO, JOSHUA; recipient as written: PHARMAIN CORPORATION, BOTHELL, WA. Development of an immunomodulating peptide as source ↗
Sep 19, 2023 NIH award 1R44CA278570-01A1 FY2023: $995,100 awarded for that fiscal year; activity R44 (SBIR); PI ALFARO, JOSHUA; recipient as written: PHARMAIN CORPORATION, BOTHELL, WA. Development of an immunomodulating peptide a source ↗
Jun 9, 2023 NIH award 4R44HL156295-02 FY2023: $967,740 awarded for that fiscal year; activity R44 (SBIR); PI CASTILLO, GERARDO M.; recipient as written: PHARMAIN CORPORATION, BOTHELL, WA. CMC of Peptide Formulation for the Treat source ↗
Jul 26, 2022 NIH award 5R44DK103553-04 FY2022: $982,292 awarded for that fiscal year; activity R44 (SBIR); PI CASTILLO, GERARDO M.; recipient as written: PHARMAIN CORPORATION, BOTHELL, WA. Subcutaneous Drug Development for Portal source ↗
May 23, 2022 NIH award 1R44HL156295-01A1 FY2022: $999,993 awarded for that fiscal year; activity R44 (SBIR); PI CASTILLO, GERARDO M.; recipient as written: PHARMAIN CORPORATION, BOTHELL, WA. CMC of Peptide Formulation for the Tre source ↗
Aug 12, 2021 NIH award 2R44DK103553-03A1 FY2021: $992,469 awarded for that fiscal year; activity R44 (SBIR); PI CASTILLO, GERARDO M.; recipient as written: PHARMAIN CORPORATION, BOTHELL, WA. Subcutaneous Drug Development for Port source ↗
Mar 22, 2018 NIH award 5R44HL134448-02 FY2018: $999,596 awarded for that fiscal year; activity R44 (SBIR); PI CASTILLO, GERARDO M.; recipient as written: PHARMAIN CORPORATION, BOTHELL, WA. Development of Chemistry, Manufacturing, source ↗
Aug 10, 2017 NIH award 1R44HL134448-01A1 FY2017: $999,661 awarded for that fiscal year; activity R44 (SBIR); PI CASTILLO, GERARDO M.; recipient as written: PHARMAIN CORPORATION, BOTHELL, WA. Development of Chemistry, Manufacturin source ↗
Jun 18, 2015 NIH award 5R43DK103553-02 FY2015: $280,313 awarded for that fiscal year; activity R43 (SBIR); PI CASTILLO, GERARDO M.; recipient as written: PHARMAIN CORPORATION, BOTHELL, WA. Subcutaneous Drug Development for Portal source ↗
Feb 4, 2015 NIH award 5R43AI107953-02 FY2015: $299,815 awarded for that fiscal year; activity R43 (SBIR); PI CASTILLO, GERARDO M.; recipient as written: PHARMAIN CORPORATION, BOTHELL, WA. Medical countermeasure after radiation e source ↗
Sep 19, 2014 NIH award 1R43DK103553-01 FY2014: $293,272 awarded for that fiscal year; activity R43 (SBIR); PI CASTILLO, GERARDO M.; recipient as written: PHARMAIN CORPORATION, BOTHELL, WA. Subcutaneous Drug Development for Portal source ↗
Aug 18, 2014 NIH award 5R44DK084724-04 FY2014: $749,606 awarded for that fiscal year; activity R44 (SBIR); PI CASTILLO, GERARDO M.; recipient as written: PHARMAIN CORPORATION, BOTHELL, WA. EGF/Gastrin for Islet Regeneration source ↗
Feb 5, 2014 NIH award 1R43AG042208-01A1 FY2014: $225,000 awarded for that fiscal year; activity R43 (SBIR); PI CASTILLO, GERARDO M.; recipient as written: PHARMAIN CORPORATION, BOTHELL, WA. Vasoactive Intestinal Peptide for the source ↗
Feb 5, 2014 NIH award 1R43AI107953-01A1 FY2014: $299,872 awarded for that fiscal year; activity R43 (SBIR); PI CASTILLO, GERARDO M.; recipient as written: PHARMAIN CORPORATION, BOTHELL, WA. Medical countermeasure after radiation source ↗
Sep 5, 2013 NIH award 2R44DK084724-03A1 FY2013: $794,040 awarded for that fiscal year; activity R44 (SBIR); PI CASTILLO, GERARDO M.; recipient as written: PHARMAIN CORPORATION, BOTHELL, WA. EGF/Gastrin for Islet Regeneration source ↗
Aug 8, 2013 NIH award 5R43AI098137-02 FY2013: $145,203 awarded for that fiscal year; activity R43 (SBIR); PI REICHSTETTER, SANDRA; recipient as written: PHARMAIN CORPORATION, BOTHELL, WA. Vasoactive intestinal peptide for the tr source ↗
Apr 8, 2013 NIH award 5R43AI098130-02 FY2013: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI CASTILLO, GERARDO M.; recipient as written: PHARMAIN CORPORATION, BOTHELL, WA. Nanocarrier formulated enzyme for the tr source ↗
Sep 6, 2012 NIH award 1R43AI098137-01 FY2012: $226,765 awarded for that fiscal year; activity R43 (SBIR); PI REICHSTETTER, SANDRA; recipient as written: PHARMAIN CORPORATION, BOTHELL, WA. Vasoactive intestinal peptide for the tr source ↗
Jun 21, 2012 NIH award 5R43AI094664-02 FY2012: $299,973 awarded for that fiscal year; activity R43 (SBIR); PI CASTILLO, GERARDO M.; recipient as written: PHARMAIN CORPORATION, BOTHELL, WA. Nanocarrier-formulated NF-kB inhibitors source ↗
May 9, 2012 NIH award 1R43AI098130-01A1 FY2012: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI CASTILLO, GERARDO M.; recipient as written: PHARMAIN CORPORATION, BOTHELL, WA. Nanocarrier formulated enzyme for the source ↗
Jul 13, 2011 NIH award 1R43AI094664-01A1 FY2011: $299,976 awarded for that fiscal year; activity R43 (SBIR); PI CASTILLO, GERARDO M.; recipient as written: PHARMAIN CORPORATION, BOTHELL, WA. Nanocarrier-formulated NF-kB inhibitor source ↗
Jul 8, 2011 NIH award 5R44AA019584-03 FY2011: $432,304 awarded for that fiscal year; activity R44 (SBIR); PI CASTILLO, GERARDO M.; recipient as written: PHARMAIN CORPORATION, BOTHELL, WA. Nanocarrier-formulated anti-fibrotic pep source ↗
Sep 6, 2010 NIH award 5R43DK084724-02 FY2010: $229,824 awarded for that fiscal year; activity R43 (SBIR); PI CASTILLO, GERARDO M.; recipient as written: PHARMAIN CORPORATION, BOTHELL, WA. EGF/Gastrin for Islet Cell Regeneration source ↗
Jul 20, 2010 NIH award 5R43AI082723-02 FY2010: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI REICHSTETTER, SANDRA; recipient as written: PHARMAIN CORPORATION, BOTHELL, WA. Long-acting VIP formulations for the tre source ↗
Jun 28, 2010 NIH award 4R44AA019584-02 FY2010: $350,624 awarded for that fiscal year; activity R44 (SBIR); PI CASTILLO, GERARDO M.; recipient as written: PHARMAIN CORPORATION, BOTHELL, WA. Nanocarrier-formulated anti-fibrotic pep source ↗
Mar 29, 2010 NIH award 1R44AA019584-01 FY2010: $160,363 awarded for that fiscal year; activity R44 (SBIR); PI CASTILLO, GERARDO M.; recipient as written: PHARMAIN CORPORATION, BOTHELL, WA. Nanocarrier-formulated anti-fibrotic pep source ↗
Feb 26, 2010 NIH award 1R43DK085754-01 FY2010: $223,422 awarded for that fiscal year; activity R43 (SBIR); PI BOLOTIN, ELIJAH M.; recipient as written: PHARMAIN CORPORATION, BOTHELL, WA. Outpatient treatment for portal hypertensi source ↗
Sep 1, 2009 NIH award 3R44DK069727-05S1 FY2009: $115,668 awarded for that fiscal year; activity R44 (SBIR); PI BOLOTIN, ELIJAH M.; recipient as written: PHARMAIN CORPORATION, BOTHELL, WA. Long Acting Native GLP-1 formulations fo source ↗
Sep 1, 2009 NIH award 1R43DK084724-01 FY2009: $213,784 awarded for that fiscal year; activity R43 (SBIR); PI CASTILLO, GERARDO M.; recipient as written: PHARMAIN CORPORATION, BOTHELL, WA. EGF/Gastrin for islet cell regeneration source ↗